文献速递类风湿关节炎

Medicare Part D 中新型抗风湿药物覆盖慷慨度分析

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand-Alone Part D Plans.
PubMed 文献 · Arthritis Rheumatol · 2026-04-20

该研究利用2022-2026年Part D处方集数据,评估治疗复发性类风湿关节炎的自我给药DMARDs覆盖情况。结果显示依那西普、阿达木单抗和乌帕替尼覆盖较完整,但阿巴西普等药物覆盖较低,仅少数计划覆盖所有作用机制。

要点

  • 依那西普、阿达木单抗和乌帕替尼在五年期间覆盖相对完整(>94%)。
  • 仅10.4%独立和37.6% Medicare Advantage Part D计划覆盖所有作用机制。
  • 2026年仅0.3%独立和21.2% MA计划覆盖阿巴西普。

核心结论

  • 自我给药DMARDs在不同作用机制间日益被排除,且计划类型间覆盖异质性提示RA患者获取最佳治疗可能存在障碍。

主要发现

  • 五年期间,依那西普和阿达木单抗(TNF抑制剂)及乌帕替尼(JAK抑制剂)覆盖相对完整(>94%)。
  • 戈利木单抗、赛妥珠单抗、阿巴西普、沙利鲁单抗和巴瑞替尼覆盖较低。
  • 仅10.4%独立和37.6% Medicare Advantage Part D计划覆盖所有作用机制,主要因阿巴西普覆盖低。
  • 2026年仅0.3%独立和21.2% MA Part D计划覆盖阿巴西普。
  • IL-6抑制剂覆盖增加,可能因2024年托珠单抗生物类似药可用。

临床怎么用

  • 临床选择自我给药DMARDs时需考虑Part D计划类型及处方集覆盖差异,尤其阿巴西普覆盖有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examine coverage of self-administered disease-modifying antirheumatic drugs (DMARDs) in Medicare Part D. METHODS: Using 2022-2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin-6 (IL-6) inhibitors, and JAK inhibitors. We measured (1) coverage of individual DMARDs and (2) the generosity of coverage between classes (the share of plans covering at least one drug in each class) and within classes (the share of covered drugs within each class). RESULTS: We included 26,915 plan-year observations, representing 217.6 million enrolled beneficiaries from 2022 to 2026. In the five-year period, coverage was relatively complete (>94%) for etanercept and adalimumab (TNF inhibitors) and upadacitinib (JAK inhibitor). However, coverage was lower for golimumab and certolizumab (TNF inhibitors), abatacept (the sole T cell costimulatory modulator), sarilumab (IL-6 inhibitor), and baricitinib (JAK inhibitor). Moreover, only 10.4% and 37.6% of stand-alone and Medicare Advantage (MA) Part D plans, respectively, covered all mechanisms of action, mostly due to low coverage of abatacept. In 2026, only 0.3% and 21.2% of stand-alone and MA Part D plans, respectively, covered abatacept. On the other hand, coverage increased for IL-6 inhibitors, likely due to the availability of biosimilar drugs for tocilizumab in 2024. CONCLUSION: The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kwon Y, Corty RW, Dusetzina SB, et al. Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand-Alone Part D Plans. Arthritis Rheumatol. 2026. PMID: 41841636. doi:10.1002/art.70132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。